Zobrazeno 1 - 10
of 254
pro vyhledávání: '"PVTT"'
Publikováno v:
Liver Research, Vol 8, Iss 3, Pp 141-151 (2024)
Hepatocellular carcinoma (HCC) is the sixth most prevalent form of cancer globally and the third leading cause of cancer-related mortality. The incidence of portal vein tumor thrombosis (PVTT) in HCC patients is 21% at one year and 46% at three years
Externí odkaz:
https://doaj.org/article/0a485adec1b34749b96133a23bf52e4f
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Background and AimsPortal vein tumor thrombus (PVTT) occurs frequently in hepatocellular carcinoma (HCC) patients. However, there is currently no satisfactory treatment. Radiotherapy (RT) and tyrosine kinase inhibitors (TKI) are currently commonly us
Externí odkaz:
https://doaj.org/article/c4f37227028042bb948dc76eec0aaee1
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThis study aimed to assess the effectiveness and safety of vascular intervention combined with lenvatinib versus vascular intervention alone in the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT),
Externí odkaz:
https://doaj.org/article/cf9afd8088554c75b18d5af18a3e1af3
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 10, Pp 1587-1593 (2023)
Yuan Tian,1,* Wenbiao Jin,1,* Honghua Sun,1 Dehao Jin,2 Dongxu Kang,1 Zhiyu Li,1 Longzhen Piao1 1Department of Oncology, The Affiliated Hospital of Yanbian University, Yanji City, Jilin Province, People’s Republic of China; 2Department of R
Externí odkaz:
https://doaj.org/article/b7d0c15031d7478aa9f83a1d49d4449f
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
PurposeTo evaluate the characteristic of blood supply of liver portal vein tumor thrombus (PVTT) using perfusion indexes and spectral parameters.MethodsBetween July 2020 and December 2022, the study enrolled 25 liver cancer patients completed with PV
Externí odkaz:
https://doaj.org/article/ffeb95a95319457681ddebd73d744840
Publikováno v:
Current Oncology, Vol 30, Iss 1, Pp 1243-1254 (2023)
Background: Transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) may enhance the efficacy of treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT); however, it remains unclear. We aim to
Externí odkaz:
https://doaj.org/article/362f5fdede42400bb3e9e67f16767b0f
Autor:
Zili Hu, Zhenyun Yang, Jiongliang Wang, Yizhen Fu, Zhiwen Hu, Zhongguo Zhou, Minshan Chen, Yaojun Zhang
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background/purpose: The prognosis of hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) is generally poor and hepatectomy is optional for these patients. This study aims to explore the survival benefits of neoadjuvant hepa
Externí odkaz:
https://doaj.org/article/cf710ee031d1411baea8262afaaec3af
Autor:
Meng Sha, Chen Chen, Chuan Shen, Seogsong Jeong, Han-yong Sun, Ning Xu, Hua-lian Hang, Jie Cao, Ying Tong
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundHepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) have conventionally been regarded as a contraindication for liver transplantation (LT). However, the outcomes of deceased donor liver transplantation (DDLT) in p
Externí odkaz:
https://doaj.org/article/0571c037399b439d9b4941b99eebf6e8
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
ObjectiveTo analyze the CT findings of hepatoid adenocarcinoma of the stomach (HAS) and improve the diagnosis accuracy of this condition.MethodsThe CT images of 22 pathologically confirmed HAS patients were analyzed retrospectively. We investigated t
Externí odkaz:
https://doaj.org/article/d44b51d4c1ff4c25aa42393c8de57285
Autor:
Jin-Kai Feng, Zong-Han Liu, Zhi-Gang Fu, Zong-Tao Chai, Ju-Xian Sun, Kang Wang, Yu-Qiang Cheng, Hong-Fei Zhu, Yan-Jun Xiang, Li-Ping Zhou, Jie Shi, Wei-Xing Guo, Jian Zhai, Shu-Qun Cheng
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
PurposeThis study aimed to assess the efficacy and safety of a triple therapy that comprises transarterial chemoembolization (TACE), antiangiogenic-targeted therapy, and programmed death-1 (PD-1) inhibitors in a real-world cohort of patients with unr
Externí odkaz:
https://doaj.org/article/8a725b6662e54cd288062e6f0190f9c0